Clinical Read2026-06-01

NUBEQA (darolutamide) - (ARACOG)

Name: NUBEQA (darolutamide) - (ARACOG)
Start: 2026-06-01

Bayer AG ADRBAYRY

Indication: Non-metastatic castration resistant prostate cancer (CRPC), Metastatic hormone sensitive prostate cancer (HSPC)
Stage: phase2
Event: Phase 2